Form 4 for SEPN Septerna, Inc.
Accepted 2026-08-05 19:00:03 ET · period of report 2026-08-03 · accession 0001193125-26-335820 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-05 19:00 | 2026-08-03 | SEPN | Long Daniel D. | SVP, Drug Discovery | M - OptEx | $2.76 | +3,334 | 99.7K | +3% | +$9,202 |
| DMT | 2026-08-05 19:00 | 2026-08-03 | SEPN | Long Daniel D. | SVP, Drug Discovery | S - Sale+OE | $34.47 | -3,334 | 96.4K | -3% | -$114.9K |
| DMT | 2026-08-05 19:00 | 2026-08-03 | SEPN | Long Daniel D. | SVP, Drug Discovery | M - OptEx | $0.00 | -3,334 | 12.4K | -21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-03 | M | A | 1,816 | $2.76 | 98,228 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-03 | M | A | 1,518 | $2.76 | 99,746 | D | — | — | |
| 3 | Common | Common Stock | 2026-08-03 | S | D | 1,000 | $33.98 | 98,746 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026. (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.39 to $34.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 4 | Common | Common Stock | 2026-08-03 | S | D | 2,334 | $34.68 | 96,412 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026. (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.43 to $35.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-08-03 | M | D | 1,816 | $0.00 | 5,227 | D | $2.76 · — to 2033-11-11 | 1,816 Common Stock | (F4) 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-08-03 | M | D | 1,518 | $0.00 | 12,418 | D | $2.76 · — to 2034-03-19 | 1,518 Common Stock | (F5) 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. |